Journal
ACS NANO
Volume 17, Issue 23, Pages 23872-23888Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.3c08147
Keywords
antioxidants; acute lung injury; acute respiratorydisease syndrome; nanomedicine; reactive oxygenspecies; molybdenum
Ask authors/readers for more resources
This study developed molybdenum nanodots as a functional nanomaterial for the treatment of acute lung injury. Through scavenging reactive oxygen species and inhibiting inflammatory responses, the nanodots significantly improved the condition of mice with acute lung injury and protected lung tissues. The findings offer a promising therapeutic agent for patients suffering from acute respiratory disease syndrome.
Acute respiratory disease syndrome (ARDS) is a common critical disease with high morbidity and mortality rates, yet specific and effective treatments for it are currently lacking. ARDS was especially apparent and rampant during the COVID-19 pandemic. Excess reactive oxygen species (ROS) production and an uncontrolled inflammatory response play a critical role in the disease progression of ARDS. Herein, we developed molybdenum nanodots (MNDs) as a functional nanomaterial with ultrasmall size, good biocompatibility, and excellent ROS scavenging ability for the treatment of acute lung injury (ALI). MNDs, which were administered intratracheally, significantly ameliorated lung oxidative stress, inflammatory response, protein permeability, and histological severity in ALI mice without inducing any safety issues. Importantly, transcriptomics analysis indicated that MNDs protected lung tissues by inhibiting the activation of the Nod-like receptor protein 3 (NLRP3)-dependent pyroptotic pathway. This work presents a promising therapeutic agent for patients suffering from ARDS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available